Norinchukin Bank The Buys 4,894 Shares of Eli Lilly and Company $LLY

Key Points

• Norinchukin Bank increased its stake in Eli Lilly and Company by 14.4%, acquiring an additional 4,894 shares, bringing its total holdings to 38,942 shares valued at approximately $32.16 million.
• Eli Lilly reported a quarterly EPS of $6.31, exceeding analyst estimates, with revenues rising by 37.6% year-over-year to $15.56 billion.
• The company declared a quarterly dividend of $1.50 per share, with a payout ratio of 39.22%, contributing to an annualized dividend yield of 0.9%.

Norinchukin Bank The raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 14.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,942 shares of the company's stock after buying an additional 4,894 shares during the quarter. Norinchukin Bank The's holdings in Eli Lilly and Company were worth $32,163,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. CW Advisors LLC increased its holdings in Eli Lilly and Company by 43.4% in the 1st quarter. CW Advisors LLC now owns 69,680 shares of the company's stock valued at $57,808,000 after buying an additional 21,074 shares during the period. Brown Shipley& Co Ltd increased its holdings in Eli Lilly and Company by 1.3% in the 1st quarter. Brown Shipley& Co Ltd now owns 5,132 shares of the company's stock valued at $4,239,000 after buying an additional 65 shares during the period. Wormser Freres Gestion increased its holdings in Eli Lilly and Company by 41.4% in the 1st quarter. Wormser Freres Gestion now owns 471 shares of the company's stock valued at $389,000 after buying an additional 138 shares during the period. Atika Capital Management LLC increased its holdings in Eli Lilly and Company by 1.4% in the 1st quarter. Atika Capital Management LLC now owns 33,100 shares of the company's stock valued at $27,338,000 after buying an additional 450 shares during the period. Finally, Partners Capital Investment Group LLP increased its holdings in Eli Lilly and Company by 100.4% in the 1st quarter. Partners Capital Investment Group LLP now owns 2,020 shares of the company's stock valued at $1,668,000 after buying an additional 1,012 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Leerink Partners restated a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $950.17.

Eli Lilly and Company Trading Up 0.1%

NYSE:LLY traded up $0.9090 during mid-day trading on Friday, hitting $710.7290. 3,217,264 shares of the company's stock were exchanged, compared to its average volume of 6,973,298. The company has a 50 day simple moving average of $754.70 and a 200-day simple moving average of $790.90. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.48. The firm has a market capitalization of $672.68 billion, a P/E ratio of 46.45, a PEG ratio of 0.99 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Insider Transactions at Eli Lilly and Company

In other news, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.